Synaptogenix Inc (SNPX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Synaptogenix Inc (SNPX) has a cash flow conversion efficiency ratio of -0.042x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-749.07K) by net assets ($17.96 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see SNPX company net worth for the company's overall valuation and market capitalisation.
Synaptogenix Inc - Cash Flow Conversion Efficiency Trend (2018–2024)
This chart illustrates how Synaptogenix Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Synaptogenix Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Synaptogenix Inc ranked by their cash flow conversion efficiency. Explore cash flow quality index of Synaptogenix Inc to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
NRB Industrial Bearings Limited
NSE:NIBL
|
-0.012x |
|
Plascar Participações Industriais S.A
SA:PLAS3
|
-0.023x |
|
EA Holdings Bhd
KLSE:0154
|
-0.050x |
|
Eros International Media Limited
NSE:EROSMEDIA
|
-0.061x |
|
Euro Manganese Inc
AU:EMN
|
3.412x |
|
AB Effectenbeteiligungen AG
STU:JPH
|
N/A |
|
NETUM GROUP OYJ
F:79J
|
N/A |
|
Sersol Bhd
KLSE:0055
|
-0.031x |
Annual Cash Flow Conversion Efficiency for Synaptogenix Inc (2018–2024)
The table below shows the annual cash flow conversion efficiency of Synaptogenix Inc from 2018 to 2024. View latest Synaptogenix Inc stock price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $6.78 Million | $-4.88 Million | -0.721x | -256.43% |
| 2023-12-31 | $25.58 Million | $-5.17 Million | -0.202x | +36.13% |
| 2022-12-31 | $35.41 Million | $-11.21 Million | -0.317x | -21.86% |
| 2021-12-31 | $33.53 Million | $-8.71 Million | -0.260x | +83.52% |
| 2020-12-31 | $5.14 Million | $-8.10 Million | -1.577x | -131.06% |
| 2019-12-31 | $17.42 Million | $-11.89 Million | -0.682x | -135.14% |
| 2018-12-31 | $26.52 Million | $-7.70 Million | -0.290x | -- |
About Synaptogenix Inc
TAO Synergies Inc. operates as a biopharmaceutical company. The company is primarily focused on developing a product platform based upon Bryostatin-1, for the treatment of Alzheimer's disease (AD), which is in the clinical testing stage. It is also evaluating potential therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X synd… Read more